Close Menu

NEW YORK (GenomeWeb) – Quidel reported after the close of the market on Tuesday that its first quarter revenues rose 130 percent year over year, primarily driven by incremental revenues from an acquired cardiac immunoassay business and sales of influenza immunoassay products.

For the three months ended March 31, revenues rose to $169.1 million from $73.7 million in Q1 2017, and beating the average analysts' estimate of $150.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.